Evaluating tumor volume in the body; primarily used for monitoring recurrence
CA-125 (Cancer Antigen-125)
A tumor marker useful for monitoring ovarian cancer by measuring an antigen to epithelial neoplasms circulating in blood serum.
0 - 35 U/mL. Normal range may vary somewhat according to institutional experience. Levels above 35 suggest the presence of ovarian tumor.
CEA (Carcinoembryonic Antigen)
A blood test measuring the presence of an antigen in malignancies arising in entodermal (embryonic) or gastrointestinal tissue. CEA assay is nonspecific for identifying a primary site, but it does indicate the presence of malignancy. Smokers may have an elevated CEA without malignant disease.
< 2.5 ng/ml. Normal range may vary somewhat according to institutional experience. Levels > 10 ng/ml suggest extensive disease and levels > 20 ng/ml suggest metastatic disease.
TPA (Tissue Polypeptide Antigen)
An antigen marker for cancers of gynecologic sites, bladder, and lung; nonspecific to ovarian cancer; elevated levels indicate presence of malignancy.
For germ cell tumors
Alpha-fetoprotein: A serum test used as a tumor marker for teratoma or embryonal carcinoma of the ovary. Elevated alpha-fetoprotein levels are not found in other histologies of ovarian cancer, although they may be found in patients with hepatocellular cancer. Note: Observe the date of an alpha-fetoprotein study carefully. Record a pre-operative study only. Alpha-fetoprotein is also used as a marker postoperatively to monitor residual tumor. Also called: aFP, AFP, alpha-fetoglobulin.
Adults: < 15 ng/ml.
Beta Subunit HCG (Human Chorionic Gonadotropin):
A serum test used as a tumor marker for germ cell ovarian carcinoma. When the presence of B-HCG is detected in serum it always indicates a malignancy. Also called: ?-HCG, beta-HCG, beta chain HCG. Note: Observe the date of the beta-HCG study carefully. Record a pre-operative study only. Beta-HCG is also used as a marker postoperatively to monitor residual tumor and the effectiveness of therapy. In patients with germ cell ovarian cancer who have had an oophorectomy, the presence of beta-HCG will confirm the patient has residual cancer that requires further treatment. However, when beta-HCG does not exist in the serum, the presence of active cancer cannot be excluded, especially in patients who have been previously treated.
Click here to view the Tumor Markers page of the Diagnostic Tests module for more information.